Beyond The Fine Print: OPDP's 2026 DTC Letters Redefine Net Impression

AGG Food & Drug attorneys Alan Minsk, Laura LaBrie, and Grace Gluck authored an article for Life Science Leader sharing insight on how Office of Prescription Drug Promotion’s (“OPDP’s”) 2026 untitled letters have indicated that the agency could be placing greater emphasis on consumer takeaways and net-impressions when evaluating direct-to-consumer promotion. 

The OPDP appears to be interested in the impact on overall consumer takeaways related to drug promotions’ omission of material risk information, minimization of safety concerns, broad efficacy messaging, and failure to communicate important limitations on use. 

“For life sciences companies, the lesson extends beyond legal or regulatory risk. The challenge is operational and strategic,” said Alan, Laura, and Grace. “As promotional ecosystems become more complex and consumer-facing communications continue to expand across channels, organizations that integrate compliance considerations earlier in campaign development may be better positioned to preserve both regulatory credibility and commercial effectiveness.” 

“In short, the recent letters suggest that traditional disclosure practices may provide limited protection when the overall consumer takeaway remains misleading,” the attorneys noted. “Whether viewed as an enforcement trend or an evolving standard, net impression is increasingly becoming the lens through which DTC promotion is evaluated.” 

To view the full article, please click here.